Item 5. Other Information
Item 5. Other Information
None.
56
Table of Contents
Item 6. Exhibits
INCORPORATED BY REFERENCE
EXHIBIT
NUMBER DESCRIPTION OF EXHIBITS FORM FILE
NUMBER EXHIBIT FILING
DATE
10.1 Support Agreement, dated as of April 14, 2020, among Lantheus Holdings, Inc., Velan Capital, L.P., Altiva Management Inc., Velan Capital Partners LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Principals GP LLC, Velan Capital Management LLC, Balaji Venkataraman, Deepak Sarpangal and Kevin McNeill
8-K 001-36569 10.1 April 14, 2020
10.2* Amendment No. 1 to Credit Agreement, dated as of June 19, 2020, among Lantheus Medical Imaging, Inc., as borrower, Lantheus Holdings, Inc. and Wells Fargo Bank, N.A., as administrative agent and collateral agent*
10.3 Contingent Value Rights Agreement, dated as of June 19, 2020, by and between Lantheus Holdings, Inc. and Computershare Trust Company, N.A., as rights agent.
8-K 001-36569 10.1 June 22, 2020
10.4 Lantheus Holdings, Inc. 2005 Stock Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2005 Stock Incentive Plan).
S-8 333-239491 4.4 June 26, 2020
10.5 Lantheus Holdings, Inc. 2018 Performance Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan).
S-8 333-239491 4.5 June 26, 2020
10.6†
License Agreement, dated February 3, 2011, by and between Salix Pharmaceuticals, Inc., the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Excelsior Life Sciences Ireland Limited.
10-Q 000-23143 10.37(16) May 10, 2011
10.7†
Lease, dated December 31, 2015, between the Registrant and WTC TOWER 1 LLC.
8-K 000-23143 10.46 (21) January 5, 2016
10.8†
Loan Agreement, dated November 4, 2016, between the Registrant through its wholly-owned subsidiary MNTX Royalties Sub LLC and Healthcare Royalty Partners III, L.P.
8-K 000-23143 10.53(24) November 7, 2016
31.1* Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).
31.2* Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).
32.1** Certification pursuant to 18 U.S.C. Section 1350.
101.INS* Inline XBRL Instance Document
101.SCH* Inline XBRL Taxonomy Extension Schema Document
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Filed herewith.
** Furnished herewith.
† Confidential treatment granted as to certain portions omitted and filed separately with the Commission.
+ Indicates management contract or compensatory plan or arrangement.
57
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LANTHEUS HOLDINGS, INC.
By: /s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: President and Chief Executive Officer
(Principal Executive Officer)
Date: July 31, 2020
LANTHEUS HOLDINGS, INC.
By: /s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)
Date: July 31, 2020
58
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.